论文部分内容阅读
目的评估绝经期乳腺癌妇女服用他莫昔芬(tamoxifen,TAM)后Ki-67、Fas及Fasl在子宫内膜中的表达。方法2001-01-2004-08采用免疫组化法测定北京天坛医院妇科46例TAM组及18例对照萎缩内膜组子宫内膜中Ki-67、Fas、Fasl的表达。结果TAM组与对照组比较,Ki-67及Fasl呈明显高表达(分别为15·41±4·83、9·05±5·52,P=0·009;0·46±0·14、0·39±0·10,P=0·037);Fas未呈高表达(0·28±0·13:0·31±0·11,P=0·387)。结论TAM能够引起绝经期子宫内膜增生,并不促进细胞凋亡,这些细胞增殖与凋亡因子及其发挥作用的通路可能在绝经后TAM服用者子宫内膜病变的发病机制中起作用。
Objective To evaluate the expression of Ki-67, Fas and Fasl in endometrium of postmenopausal women with tamoxifen (TAM). Methods The expression of Ki-67, Fas and Fasl in the endometrium of 46 cases of TAM group and 18 cases of control atrophic endometrium from Beijing Tiantan Hospital were measured by immunohistochemistry between January 2001 and August 2004. Results The expression of Ki-67 and Fasl in TAM group was significantly higher than that in control group (15.41 ± 4.83,9.0 ± 5.52, P = 0.009, 0.46 ± 0.14, 0 · 39 ± 0 · 10, P = 0 · 037); Fas was not overexpressed (0.28 ± 0.13: 0.31 ± 0.11, P = .387). Conclusion TAM can induce endometrial hyperplasia in menopause and does not promote apoptosis. The proliferation and apoptosis of these cells may play a role in the pathogenesis of endometrial lesions in postmenopausal TAM patients.